人民财讯10月28日电，海思科（002653）10月28日公告，获得创新药HSK44459片新适应症IND申请 《受理通知书》，适应症为炎症性肠病。海思科同日发布2025年第三季度报告，第三季度实现归母净利 润1.66亿元，同比下降23.32%。 ...

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the clinical trial application for HSK44459 tablets, aimed at treating inflammatory bowel disease [1] Group 1: Product Development - HSK44459 tablets are independently developed by the company for the treatment of inflammatory bowel disease [1] - Preclinical research results indicate that HSK44459 has independent intellectual property rights, confirmed efficacy, and good safety [1] Group 2: Clinical Trials - HSK44459 tablets have already received clinical trial approval notices for other indications, including interstitial lung disease, Behçet's disease, psoriasis, and atopic dermatitis, all of which are currently undergoing Phase II clinical studies [1]

海思科公告，第三季度营收为12.99亿元，同比增长22.05%；净利润为1.66亿元，下降23.32%。前三季 度营收为33亿元，同比增长19.95%；净利润为2.95亿元，下降22.66%。 ...

海思科医药集团股份有限公司 2025 年第三季度报告 证券代码：002653 证券简称：海思科 公告编号：2025-116 海思科医药集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个 别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 1 海思科医药集团股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,299,291,566.83 | 22.05% | ...

证券代码：002653 证券简称：海思科 公告编号：2025-117 海思科医药集团股份有限公司 炎症性肠病（IBD）是一组慢性胃肠道非特异性炎性疾病，包括 溃疡性结肠炎（UC）和克罗恩病（CD），主要临床表现包括腹痛、腹 泻、黏液脓血便、瘘管以及肛周病变，病情缓解与复发交替，可伴随 患者终生。 IBD常用的治疗药物有氨基水杨酸、激素、硫唑嘌呤、环孢素、 沙利度胺等传统制剂，以及英夫利昔单抗、阿达木单抗、维得利珠单 抗等生物制剂，但这些治疗对很大一部分患者疗效不佳，或因不良反 应太大导致患者无法耐受。对于难治性IBD，患者亟需有效的替代方 1 案。 关于获得创新药 HSK44459 片新适应症 IND 申请 《受理通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到 国家药品监督管理局下发的《受理通知书》，基本情况如下： | 药品名称 | | 剂型 | 申请事项 | 适应症 | 受理号 | | --- | --- | --- | --- | --- | --- | | HSK44459 | 片 ...

公司创始人曾为"医药女王" 今年61岁的范秀莲，有着"沈阳女首富""华南理工学霸"等多重标签。据公开报道，1987年，她从华南理 工大学毕业后进入国企上班，没过几年便辞职投身医药行业。凭借多年来的行业积累，2012年，她作为 创始人之一推动海思科（SZ002653，股价50.67元，市值567.46亿元）登陆A股，直到今年6月，海思科 公告称，范秀莲因退休辞去海思科董事会董事、总经理职务。 然而，这位医药领域的成功女性仍未从自己的事业中真正"退休"。 早在2013年，范秀莲就将目光投向了雪域高原，通过创立智汇矿业，她的创业历程从精密制药转向粗粝 的矿山。招股书显示，目前，范秀莲与一致行动人何前、吕喜军共同控制公司55.72%股权。 每经记者：孔泽思 每经编辑：魏官红 10月23日，西藏智汇矿业股份有限公司（以下简称智汇矿业）第二次递表港交所。作为矿业公司，公司 专注于在西藏从事锌、铅和铜的探矿、采矿、精矿生产及销售业务。 在第二次递交的资料中，智汇矿业更新了2025年前7个月的财务数据。在2024年公司收入及毛利均出现 下降后，2025年前7个月，公司业绩有所回暖。外界较为关注的是，作为公司最大的收入类别，锌 ...

人民财讯10月24日电，企查查APP显示，近日，海思科（002653）医药科技(拉萨)有限公司成立，法定 代表人为段鹏，注册资本为2亿元，经营范围包含：专业设计服务；品牌管理；企业管理；药品互联网 信息服务；药品生产；药品零售；药品批发等。企查查股权穿透显示，该公司由海思科全资持股。 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.48% from October 13 to October 17, underperforming the broader market index, the CSI 300, which fell by 2.22% [3][8] - There is a sustained enthusiasm for business development (BD) transactions in innovative drugs, with several companies entering agreements with international pharmaceutical firms [3][12] - The ESMO conference held from October 17 to 21 showcased positive advancements in multiple studies, particularly in immunotherapy and antibody-drug conjugates (ADCs), highlighting the potential of domestic biotech companies [3][11] Market Weekly Review - The pharmaceutical and biotechnology sector saw a weekly decline of 2.48%, with offline pharmacies and traditional Chinese medicine showing slight gains of 0.59% and 0.38%, respectively [8] - Medical research outsourcing, medical devices, and other biological products faced significant declines, with drops of 6.46%, 5.37%, and 3.6% respectively [8][9] - Notable stock performances included Asia-Pacific Pharmaceutical with a rise of 36.7%, while Betta Pharmaceuticals saw a decline of 17.0% [11] Industry News and Key Company Announcements Important Industry Events - On October 18, Kangfang Biologics presented data on a PD-1/VEGF dual antibody in non-small cell lung cancer at the ESMO conference, showing significant improvement in progression-free survival (PFS) [11] - On October 16, Hansa Biopharma announced a licensing agreement with Roche for the global exclusive rights to develop and commercialize HS-20110, with an upfront payment of $80 million [12] - On October 16, Prigen Biologics entered a collaboration with Gilead's Kite Pharma, receiving an upfront payment of $120 million [12][13] Company Announcements - Huayuan Biologics reported a slight decrease in total revenue for the third quarter, amounting to 936 million yuan, a 0.2% year-on-year decline [14] - Shanghai Pharmaceuticals received FDA approval for Doxycycline capsules, with projected sales of approximately $130 million in the U.S. for 2024 [14][16]

Core Viewpoint - Haikang's stock price has shown a continuous upward trend, reflecting positive market sentiment and potential investment opportunities in the pharmaceutical sector [1][2]. Company Overview - Haikang Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company is located in Zedang Town, Shannan City, Tibet [1]. - The main business activities include research and development, manufacturing, and sales of chemical drugs [1]. - Revenue composition is as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other supplementary income 0.86% [1]. Stock Performance - As of October 17, Haikang's stock price increased by 0.75% to 52.50 CNY per share, with a trading volume of 227 million CNY and a turnover rate of 0.89%. The total market capitalization is 58.796 billion CNY [1]. - The stock has risen for three consecutive days, with a cumulative increase of 6.49% during this period [1]. Fund Holdings - Southern Fund's Southern Medical Health Flexible Allocation Mixed A (000452) holds a significant position in Haikang, with 3.9138 million shares, unchanged from the previous period, accounting for 6.84% of the fund's net value [2]. - The fund has realized a floating profit of approximately 1.5264 million CNY today and 12.5241 million CNY during the three-day upward trend [2]. - The fund was established on January 23, 2014, with a current scale of 2.405 billion CNY and has achieved a year-to-date return of 45.86% [2].

分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年6月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2127.63万股，相比上期增加535.74万股。工银前沿医疗股票A（001717）位居第六 大流通股东，持股1510.01万股，相比上期增加540.00万股。汇添富创新医药混合A（006113）位居第七 大流通股东，持股1242.67万股，相比上期增加267.25万股。富国精准医疗灵活配置混合A（005176）位 居第八大流通股东，持股937.79万股，相比上期减少191.01万股。汇添富医疗服务灵活配置混合A （001417）位居第九大流通股东，持股875.93万股，相比上期减少170.31万股。香港中央结算有限公司 位居第十大流通股东，持股817.97万股，为新进股东。 责任编辑：小浪快报 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉 ...